Hemispherx Shares Jump 13+% Following Release of Summarized Phase 1/2 Data on Flu Combo

Hemispherx Biopharma, Inc. (NYSE: HEB ) (the "Company" or "Hemispherx"), presented a summary of the results of its Phase I/II study from the poster presentation entitled "Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod (Ampligen®), Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA" given at the American Society for Microbiology (ASM) Biodefense